Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Antibody Actions01:26

Antibody Actions

4.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
4.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-temporal-resolution slope-aspect deformation extraction and evolution analysis of the Xiongba landslide group based on time-series InSAR and unscented Kalman filter.

Scientific reports·2026
Same author

Mechanism of palytoxin-induced ferroptosis in HaCaT cells via targeting TrxR1.

Cell biology and toxicology·2026
Same author

Ion-Channel-Mediated Drug Repurposing Opportunities Validated by Single-Cell Perturbation in Colorectal Cancer.

International journal of molecular sciences·2026
Same author

Molecular and Cellular Mechanisms Underlying Domoic Acid-Induced Neurotoxicity and Therapeutic Drugs: A Comprehensive Review.

International journal of molecular sciences·2026
Same author

Dual-Mechanism Synergy in Chiral Conjugated Microporous Polymer Membranes for Enhanced Enantioselective Permeability.

Small (Weinheim an der Bergstrasse, Germany)·2025
Same author

Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets.

Tumori·2025

Related Experiment Video

Updated: Apr 15, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Antibody-Drug Conjugates Targeting Resistance-Associated Signaling Pathways: Recent Advances and Future Perspectives.

Dan Xie1, Chengming Yang2, Siyi Gao1

  • 1Department of Biochemistry and Molecular Biology, Naval Medical University, Shanghai 200433, China.

International Journal of Molecular Sciences
|April 14, 2026
PubMed
Summary

Antibody-drug conjugates (ADCs) offer targeted cancer therapy, but resistance limits their effectiveness. Understanding resistance mechanisms is key to developing new strategies for better patient outcomes.

Keywords:
ADCsdrug resistancemalignant tumorssignaling pathways

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) are a significant advancement in precision oncology.
  • ADCs combine targeted antibody delivery with potent cytotoxic payloads for cancer treatment.
  • Resistance to ADCs is a major challenge, leading to treatment failure.

Purpose of the Study:

  • To review the molecular mechanisms driving resistance to antibody-drug conjugates.
  • To examine the signaling pathways involved in ADC resistance.
  • To evaluate novel therapeutic strategies to overcome ADC resistance.

Main Methods:

  • Comprehensive literature review of signaling pathways in ADC resistance.
  • Analysis of molecular mechanisms contributing to intrinsic and acquired ADC resistance.
  • Evaluation of emerging therapeutic approaches to circumvent resistance.

Main Results:

  • ADC resistance involves diverse mechanisms including antigen dynamics, drug efflux, DNA repair, and apoptosis evasion.
  • Tumor cells utilize compensatory signaling networks to resist ADC therapy.
  • Specific signaling cascades are critical drivers of ADC resistance phenotypes.

Conclusions:

  • Elucidating signaling pathways is crucial for overcoming ADC resistance.
  • Novel therapeutic strategies are being developed to target these resistance mechanisms.
  • Optimizing ADC therapy requires a deep understanding of resistance biology to improve patient outcomes.